DiehmNAHoppeHDoDD.
Drug eluting balloons. Tech Vasc
Interv Radiol.
2010;13:59–63.
2.
LairdJRKatzenBTScheinertD. Nitinol stent implantation versus
balloon angioplasty for lesions in the superficial femoral artery and
proximal popliteal artery: twelve-month results from the RESILIENT
randomized trial. Circ Cardiovasc Interv.
2010;3:267–276.
3.
SchillingerMSabetiSDickP. Sustained benefit at 2 years of
primary femoropopliteal stenting compared with balloon angioplasty with
optional stenting. Circulation.
2007;115:2745–2749.
4.
SiablisDKarnabatidisDKatsanosK. Infrapopliteal application of
sirolimus-eluting versus bare metal stents for critical limb ischemia:
analysis of long-term angiographic and clinical outcome.
J Vasc Interv Radiol.
2009;20:1141–1150.
5.
GandiniRDel GiudiceCMerollaS. Treatment of chronic SFA in-stent
occlusion with combined laser atherectomy and drug-eluting balloon
angioplasty in patients with critical limb ischemia: a single-center,
prospective, randomized study. J Endovasc
Ther.
2013;20:805–814.
6.
SchillingerMMlekuschWHaumerM. Angioplasty and elective stenting of
de novo versus recurrent femoropopliteal lesions: 1-year
follow-up. J Endovasc Ther.
2003;10:288–297.
7.
DickPSabetiSMlekuschW. Conventional balloon angioplasty
versus peripheral cutting balloon angioplasty for treatment of
femoropopliteal artery in-stent restenosis: initial
experience. Radiology.
2008;248:297–302.
8.
TosakaASogaYIidaO. Classification and clinical impact of
restenosis after femoropopliteal stenting. J Am Coll
Cardiol.
2012;59:16–23.
9.
ArmstrongEJSinghSSinghGD. Angiographic characteristics of
femoropopliteal in-stent restenosis: association with long-term outcomes
after endovascular intervention. Catheter Cardiovasc
Interv. 2013 Apr 30. [Epub ahead of print]
10.
WerkMLangnerSReinkensmeierB. Inhibition of restenosis in
femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral
paclitaxel randomized pilot trial.
Circulation.
2008;118:1358–1365.
11.
TepeGZellerTAlbrechtT. Local delivery of paclitaxel to
inhibit restenosis during angioplasty of the leg. N
Engl J Med.
2008;358:689–699.
12.
SchellerBHehrleinCBockschW. Two year follow-up after treatment of
coronary in-stent restenosis with a paclitaxel-coated balloon
catheter. Clin Res Cardiol.
2008;97:773–781.
13.
UnverdorbenMVallbrachtCCremersB. Paclitaxel-coated balloon catheter
versus paclitaxel-coated stent for the treatment of coronary in-stent
restenosis. Circulation.
2009;119:2986–2994.
14.
StabileEVirgaVSalemmeL. Drug-eluting balloon for treatment of
superficial femoral artery in-stent restenosis. J Am
Coll Cardiol.
2012;60:1739–1742.
15.
YeoKKMalikULairdJR.
Outcomes following treatment of femoropopliteal in-stent
restenosis: a single center experience. Catheter
Cardiovasc Interv.
2011;78:604–608.
16.
Van Den
BergJCPedrottiMCanevasciniR. Endovascular treatment of in-stent
restenosis using excimer laser angioplasty and drug eluting
balloons. J Cardiovasc Surg (Torino).
2012;53:215–222.
17.
WerkMAlbrechtTMeyerDR. Paclitaxel-coated balloons reduce
restenosis after femoro-popliteal angioplasty: evidence from the randomized
PACIFIER trial. Circ Cardiovasc Interv.
2012;5:831–840.
18.
DerksenWJGisbertzSSHellingsWE. Predictive risk factors for
restenosis after remote superficial femoral artery
endarterectomy. Eur J Vasc Endovasc Surg.
2010;39:597–603.
19.
HoGHvan BurenPAMollFL. The importance of revision of early
restenosis after endovascular remote endarterectomy in SFA occlusive
disease. Eur J Vasc Endovasc Surg.
2000;19:35–42.
20.
IhnatDMDuongSTTaylorZC. Contemporary outcomes after
superficial femoral artery angioplasty and stenting: the influence of TASC
classification and runoff score. J Vasc
Surg.
2008;47:967–974.
21.
IidaOUematsuMSogaY. Timing of the restenosis following
nitinol stenting in the superficial femoral artery and the factors
associated with early and late restenoses. Catheter
Cardiovasc Interv.
2011;78:611–617.
